Skip to content

Study · Non-randomized trial · n = 30 · 2017

17 results

Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.

Camastra S, Astiarraga B, Tura A, Frascerra S, Ciociaro D, Mari A, Gastaldelli A, Ferrannini E

Diabetes, obesity & metabolism10 Jan 2017Cited by 22 (Europe PMC)

PMID27898183 (opens in a new tab)DOI10.1111/dom.12836 (opens in a new tab)PepBankPUB-27898183
Publisher pagePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, endogenous glucose production resumed at higher rates with exenatide than control between 60 and 180 minutes.

    In plain wordsIn non-diabetic patients with severe obesity, glucose production resumed at higher rates with exenatide than control after the meal.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEndogenous glucose production during meal test
    Study

    n = 30

    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    After an initial similar suppression, EGP resumed at higher rates between 60 and 180 minutes ( P = .02) in EXE vs CT, while total RaO and EGP were similar throughout the MTT.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, total oral glucose appearance was similar with exenatide and control throughout the meal test.

    In plain wordsIn non-diabetic patients with severe obesity, total oral glucose appearance was similar with exenatide and control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTotal oral glucose appearance
    Study

    n = 30

    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    After an initial similar suppression, EGP resumed at higher rates between 60 and 180 minutes ( P = .02) in EXE vs CT, while total RaO and EGP were similar throughout the MTT.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, total endogenous glucose production was similar with exenatide and control throughout the meal test.

    In plain wordsIn non-diabetic patients with severe obesity, total glucose production was similar with exenatide and control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTotal endogenous glucose production
    Study

    n = 30

    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    After an initial similar suppression, EGP resumed at higher rates between 60 and 180 minutes ( P = .02) in EXE vs CT, while total RaO and EGP were similar throughout the MTT.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, body weight decreased after exenatide treatment.

    In plain wordsIn non-diabetic patients with severe obesity, body weight decreased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 15

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Post treatment, the EXE group showed a significant reduction in body weight ( P < .001).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, the postmeal glucose peak was lower after exenatide treatment.

    In plain wordsIn non-diabetic patients with severe obesity, the postmeal glucose peak was lower after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal glucose peak
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The postmeal time-course of glucose, insulin and ISR showed a lower peak between 60 and 180 minutes in phase with a reduction in RaO ( P < .01).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, the postmeal insulin peak was lower after exenatide treatment.

    In plain wordsIn non-diabetic patients with severe obesity, the postmeal insulin peak was lower after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal insulin peak
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The postmeal time-course of glucose, insulin and ISR showed a lower peak between 60 and 180 minutes in phase with a reduction in RaO ( P < .01).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, the postmeal insulin secretion rate peak was lower after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, the postmeal insulin secretion rate peak was lower after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin secretion rate peak
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The postmeal time-course of glucose, insulin and ISR showed a lower peak between 60 and 180 minutes in phase with a reduction in RaO ( P < .01).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, oral glucose appearance decreased during the postmeal peak period after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, oral glucose entered circulation more slowly during the postmeal peak after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseOral glucose appearance rate
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The postmeal time-course of glucose, insulin and ISR showed a lower peak between 60 and 180 minutes in phase with a reduction in RaO ( P < .01).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  9. 09HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, postmeal glucagon response decreased after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, postmeal glucagon response decreased after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal glucagon response
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    In EXE, the postmeal glucagon, GLP1 and GIP responses were reduced ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  10. 10HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, postmeal GLP1 response decreased after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, postmeal GLP1 response decreased after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal GLP1 response
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    In EXE, the postmeal glucagon, GLP1 and GIP responses were reduced ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  11. 11HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, postmeal GIP response decreased after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, postmeal GIP response decreased after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal GIP response
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    In EXE, the postmeal glucagon, GLP1 and GIP responses were reduced ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  12. 12HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, exenatide did not change fasting lipolysis.

    In plain wordsIn non-diabetic patients with severe obesity, exenatide did not change fasting fat breakdown.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFasting lipolysis
    Study

    n = 15

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial lipolysis and ß-cell function were unaltered by active treatment.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  13. 13HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, exenatide did not change postprandial lipolysis.

    In plain wordsIn non-diabetic patients with severe obesity, exenatide did not change fat breakdown after meals.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePostprandial lipolysis
    Study

    n = 15

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial lipolysis and ß-cell function were unaltered by active treatment.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  14. 14HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, exenatide did not change beta-cell function.

    In plain wordsIn non-diabetic patients with severe obesity, exenatide did not change insulin-producing cell function.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBeta-cell function
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial lipolysis and ß-cell function were unaltered by active treatment.
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  15. 15HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, hepatic insulin resistance improved after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, liver insulin resistance improved after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHepatic insulin resistance
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    HIR, AT-IR and IS were all improved after exenatide treatment ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  16. 16HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, adipose tissue insulin resistance improved after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, fat tissue insulin resistance improved after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAdipose tissue insulin resistance
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    HIR, AT-IR and IS were all improved after exenatide treatment ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.
  17. 17HumanNon-randomized trialEfficacy outcome

    In non-diabetic morbidly obese patients, insulin sensitivity improved after exenatide.

    In plain wordsIn non-diabetic patients with severe obesity, insulin sensitivity improved after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin sensitivity
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 µg twice daily · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    HIR, AT-IR and IS were all improved after exenatide treatment ( P < .05).
    2 context sentences
    Summary · context
    To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.
    Summary · context
    Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.